Trial Profile
A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in Combination With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Gemcitabine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 May 2024.
- 23 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.